Mesothelial ECM Modulators for Wound Healing and Fibrosis Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies fail to effectively address the movement of extracellular matrix (ECM) produced by mesothelial cells towards injury sites in internal organs, leading to non-healing chronic wounds or aggravated scarring and fibrosis, which are significant health and economic burdens.
Innovation Solution
Targeting mesothelial cells, which produce and move ECM, with compounds that modulate ECM movement towards injury sites, either inhibiting or promoting it, using transcription constructs, agonists/antagonists, and administration methods to specifically affect ECM production and movement.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ECM movement towards injury sites is promoted, then wound healing is improved, but excessive ECM deposition leads to fibrosis and scarring
Solution Approach 1:
The invention applies dynamics by making the ECM movement process adjustable and controllable through modulators that can dynamically regulate the movement and deposition of ECM. This allows the system to adapt ECM deposition to the specific needs of wound healing stages, promoting movement during early healing while preventing excessive deposition that would lead to fibrosis.
Solution Approach 2:
The invention utilizes parameter changes by modifying the movement parameters of ECM through pharmacological modulators. These modulators can change the rate, direction, and extent of ECM movement towards injury sites, thereby controlling the balance between sufficient ECM deposition for wound healing and preventing excessive deposition that causes fibrosis and scarring.
2Productivity
If mesothelial cells are targeted to modulate ECM movement, then ECM production and movement can be controlled, but specificity of targeting is required to avoid off-site effects
Solution Approach 1:
The invention employs intermediaries by using specific modulators that act as mediators between the targeting mechanism and the ECM movement process. These modulators specifically interact with mesothelial cells to regulate ECM movement while minimizing effects on other cell types or tissues, thereby achieving controlled ECM production and movement without significant off-site effects.
Solution Approach 2:
The invention applies local quality by enabling specific modulation of ECM movement at the injury site through mesothelial cell targeting. The modulators exert their effects locally at the site of injury where mesothelial cells are activated, allowing controlled ECM production and movement precisely where needed while leaving other areas unaffected.
3Object-generated harmful factors
If ECM movement is inhibited, then fibrosis is prevented, but wound healing is impaired
Solution Approach 1:
The invention applies periodic action by implementing temporal control over ECM movement modulation. Different modulators or dosing regimens can be applied at different time periods during wound healing: promoting ECM movement in early stages for wound closure, then inhibiting excessive movement in later stages to prevent fibrosis, thereby achieving both wound healing and fibrosis prevention through time-dependent modulation.
Solution Approach 2:
The invention utilizes partial action by applying modulators at controlled doses and durations that achieve sufficient ECM movement for wound healing without triggering excessive deposition. By carefully calibrating the degree and extent of ECM movement modulation, the system achieves the minimum necessary action for wound repair while staying below the threshold that would lead to fibrosis.
Data Source
AI summary
The present invention relates to a compound for use in a method for the modulation of movement of extracellular matrix (ECM) produced by mesothelial cells forming the surface of an internal organ, towards a site of injury of said organ of a subject suffering from or being at a risk of an injury of said organ. Additionally, the present invention relates to a compound for use in a particular in vivo screening method for identifying a modulator of movement of extracellular matrix (ECM) produced by mesothelial cells towards a site of injury of an internal organ of a subject. Further, the present invention relates to a specific in vitro screening method for identifying a modulator of the movement of ECM towards an external stimulus in a single cell suspension derived from the mesothelium.